Mesalamine
APRISO, Canasa, Lialda, Pentasa, Rowasa, sfRowasa
Aminosalicylate
NADAC/unit
$0.1039
No Shortage
Tier 1: 109.4%
PA Req: 0.3%
23 Manufacturers
31 ANDAs
Mesalamine delayed-release tablets are indicated for the treatment of moderately active ulcerative colitis in adults.
vs. brand APRISO: Generic saves up to 99% per unit
Market Intelligence
2024-03-06 Class II Recall: SUN PHARMACEUTICAL INDUSTRIES INC
2024-01-31 Class II Recall: SUN PHARMACEUTICAL INDUSTRIES INC
Generic Manufacturers
ABBVIE INCACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INCACTAVIS MID ATLANTIC LLCALEMBIC PHARMACEUTICALS LTDALKEM LABORATORIES LTDAMNEAL PHARMACEUTICALS LLCAMRING PHARMACEUTICALS INCAMTA LABS LTDANNORA PHARMA PRIVATE LTDAUROBINDO PHARMA LTDDIFGEN PHARMACEUTICALS LLCENCUBE ETHICALS PRIVATE LTDMYLAN PHARMACEUTICALS INCMYLAN SPECIALTY LPNOVAST LABORATORIES LTDNOVITIUM PHARMA LLCPADAGIS ISRAEL PHARMACEUTICALS LTDQUAGEN PHARMACEUTICALS LLCRISING PHARMA HOLDINGS INCSALIX PHARMACEUTICALS INCSANDOZ INCSINOTHERAPEUTICS INCSUN PHARMACEUTICAL INDUSTRIES LTDTAKEDA PHARMACEUTICALS USA INCTEVA PHARMACEUTICALS INCTEVA PHARMACEUTICALS USA INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.